Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.